Top

Published in:

01-04-2015 | SHORT REPORT

Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

Authors: Yasuto Yoneshima, Isamu Okamoto, Masako Arimura-Omori, Shinichi Kimura, Noriko Hidaka-Fujimoto, Eiji Iwama, Taishi Harada, Koichi Takayama, Yoichi Nakanishi

Published in: Investigational New Drugs | Issue 2/2015

Summary

Crizotinib is the first clinically available tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and is associated with the development of complex renal cysts. We now describe a 39-year-old woman who developed infected complex renal cysts during crizotinib treatment. After 10 months of such treatment, she presented with a high fever and low back pain. Computed tomography findings were consistent with complex renal cysts and perilesional inflammation. Interventions including cyst drainage and antibiotic administration contributed to diagnosis and management of the infected cysts.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566. doi:10.1038/Nature05945 CrossRefPubMed

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SHI, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan WW, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703. doi:10.1056/Nejmoa1006448 CrossRefPubMedCentralPubMed

Rothenstein JM, Letarte N (2014) Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol 21(1):19–26. doi:10.3747/Co.21.1740 CrossRefPubMedCentralPubMed

Whelan TF (2010) Guidelines on the management of renal cyst disease. Can Urol Assoc J 4(2):98–99CrossRefPubMedCentralPubMed

Tada S, Yamagishi J, Kobayashi H, Hata Y, Kobari T (1983) The incidence of simple renal cyst by computed tomography. Clin Radiol 34(4):437–439CrossRefPubMed

Sallee M, Rafat C, Zahar JR, Paulmier B, Grunfeld JP, Knebelmann B, Fakhouri F (2009) Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol CJASN 4(7):1183–1189. doi:10.2215/CJN.01870309 CrossRef

Cowley BD Jr, Rupp JC, Muessel MJ, Gattone VH 2nd (1997) Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis Off J Natl Kidney Found 29(2):265–272CrossRef

Jayapalan S, Saboorian MH, Edmunds JW, Aukema HM (2000) High dietary fat intake increases renal cyst disease progression in Han: SPRD-cy rats. J Nutr 130(9):2356–2360PubMed

Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR (2012) Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 118(21):5302–5309. doi:10.1002/cncr.27450 CrossRefPubMed

Title: Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement
Authors: Yasuto Yoneshima
Isamu Okamoto
Masako Arimura-Omori
Shinichi Kimura
Noriko Hidaka-Fujimoto
Eiji Iwama
Taishi Harada
Koichi Takayama
Yoichi Nakanishi
Publication date: 01-04-2015
Publisher: Springer US
Published in: Investigational New Drugs / Issue 2/2015
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-014-0195-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2015

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors

Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration

Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors

Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer